The analysis of tumor tissues from advanced-stage breast cancer patients demonstrated an increase in the likelihood of developing bone metastases in patients with IL-1β-positive primary tumors compared to patients with IL-1β-negative tumors. This evidence concerns the gene IL1B and breast cancer.